Partnerships Bristol Myers Squibb (collaboration and supply agreement for CM24 + nivolumab Phase 1/2 study)
Indications
Pancreatic ductal adenocarcinoma, second-line (in combination with nivolumab + chemotherapy)(Phase 2)
Status note Concluded a proof-of-concept Phase 2 study as combination therapy with an anti-PD-1 checkpoint inhibitor and chemotherapy for second-line PDAC. Further development planned upon partnering or obtaining sufficient investment.
NT219
Phase 2 · ActiveModality: Small molecule
Target IRS1/2 + STAT3
Partnerships University of Colorado Anschutz Medical Campus (research agreement for investigator-initiated Phase 2 study)
Indications
Recurrent and/or metastatic squamous cell carcinoma of the head and neck (in combination with cetuximab or pembrolizumab)(Phase 2)
Status note Concluded a Phase 1 dose-escalation study as monotherapy and in combination with cetuximab. Investigator-initiated Phase 2 study in recurrent/metastatic SCCHN initiated June 2025. Further development planned upon partnering or obtaining sufficient investment.
Status note Second tri-specific antibody generated using the CAPTN-3 platform, targeting TROP2.
Per-asset detail extracted from the 20-F filed 2026-03-19. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.